A Rare Case of Recurrent Uterine Fibroids: Uncovering a Hidden Cancer Risk
This story begins with a common issue for many women - uterine fibroids. But here's where it gets controversial... these fibroids were not your typical benign tumors. They were associated with a rare genetic condition, and what's more, they may have been a warning sign of a deadly cancer.
Uterine leiomyomas, or fibroids, are a common occurrence in women, but a specific type, known as FH-deficient leiomyomas, is extremely rare, accounting for only 1-2% of cases. These fibroids are linked to Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) syndrome, an autosomal dominant cancer syndrome caused by mutations in the FH gene. HLRCC is characterized by the presence of cutaneous and uterine leiomyomas, as well as renal cell carcinomas (RCC).
The patient, a 37-year-old woman, initially presented with heavy menstruation and blood clots. An ultrasound during pregnancy in 2010 revealed uterine leiomyoma, and she underwent her first myomectomy during a cesarean section. However, the fibroids recurred, and she underwent two more myomectomies in 2018 and 2024. The third surgery was particularly challenging due to extensive pelvic adhesions and a significant blood loss of 1000 mL.
During the third surgery, the patient's uterus was found to be enlarged and irregular, with multiple protuberances resembling fibroids. Post-operative histopathological examination revealed local cell density, and further immunohistochemical analysis confirmed FH-deficient leiomyoma. The patient also presented with a 5 cm mass lesion in the left kidney, which, upon further examination, was confirmed as RCC.
Genetic testing revealed the patient had a germline heterozygous mutation in the FH gene, leading to the diagnosis of HLRCC syndrome. RCC associated with HLRCC is an aggressive form of cancer, primarily presenting as PRCC2, and often carries a poor prognosis and high mortality rate. In this case, the renal tumors were detected at an advanced stage, and the patient underwent immunization and targeted therapy, followed by a robotic radical nephrectomy.
The key takeaway here is the importance of early diagnosis and recognition of HLRCC-associated RCC. Uterine leiomyomas are usually the reason for hospitalization in this patient group, providing an opportunity for early RCC detection. However, due to the lack of defined biomarkers and the financial burden of genetic testing, many cases go undiagnosed.
In this case, the patient's recurrent and multiple uterine fibroids, along with her young age, led to a high suspicion of FH-deficient leiomyomas. Further examinations confirmed this, and genetic testing ultimately revealed the HLRCC diagnosis. If HLRCC and RCC had been recognized earlier, the patient's prognosis and quality of life could have been significantly improved.
So, the question remains: should we be more vigilant in screening for HLRCC syndrome, especially in cases of recurrent uterine fibroids? This case highlights the potential benefits of early diagnosis and the need for further research and awareness in this area. What are your thoughts on this intriguing medical mystery?
